BERLIN (dpa-AFX) - The radiation and medical technology group Eckert & Ziegler closed the past year better than expected. According to preliminary figures, 2022 sales of around 225 million euros generated a surplus of just under 30 million euros, as the company, which is listed on the small-cap index SDax, announced in Berlin on Tuesday. This means that revenue and earnings are each expected to be around ten percent higher than management had anticipated, the statement added.

Eckert & Ziegler benefited last year from demand from the oil industry and for pharmaceutical radioisotopes. In July, however, the Group had to lower its profit forecast for 2022, partly due to a slowdown in the economy. The company had recently forecast sales of around 200 million euros and a net profit of around 27 million euros for the twelve months. Originally, however, the Berlin-based company had assumed a bottom-line profit of a good 38 million euros./tav/stk